Axon Enterprise, Inc. filings document operating results and corporate actions for a public safety technology company with Software & Services and Connected Devices activities. Form 8-K reports include shareholder letters on financial results and outlooks, product demand across TASER devices, Axon Body cameras, Axon Evidence, AI products, counter-drone offerings and real-time operations, as well as material-event disclosures tied to capital structure.
Proxy materials cover board composition, shareholder meeting matters, executive compensation and equity awards. Other 8-K and 8-K/A filings record director election updates and the redemption and settlement of 0.50% convertible senior notes due 2027, including the disclosure that no convertible notes remained outstanding after the redemptions and conversions.
Jennifer H. Mak, Chief Accounting Officer of Axon Enterprise, Inc. (AXON), reported a sale of 77 shares of common stock on 09/15/2025. The sale was effected under a Rule 10b5-1 trading plan adopted March 14, 2025, and related to shares issued upon settlement of vested restricted stock units. The reported sale price was $760 per share. After the transaction, Ms. Mak beneficially owned 15,003 shares directly. The Form 4 was signed by an attorney-in-fact on her behalf.
Brittany Bagley, identified as AXON's COO & CFO, reported a sale of 870 shares of AXON common stock on 09/15/2025 at a price of $773.247 per share. After the transaction she beneficially owned 113,022 shares, held directly. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Jeri Williams, a director of Axon Enterprise, Inc. (AXON), reported a sale of company stock on 09/11/2025. The Form 4 shows she disposed of 100 shares of Common Stock in one or more trades at a weighted average price of $752.5434 per share, with execution prices ranging from $752.50 to $752.61. Following the reported transaction, the filing lists 1,416 shares beneficially owned by Ms. Williams in a direct ownership form. The filing was signed on her behalf by an attorney-in-fact, Isaiah Fields.
Form 144 filed for AXON ENTERPRISE, INC. The notice reports a proposed sale of 870 shares of common stock through Morgan Stanley Smith Barney LLC on 09/15/2025 on NASDAQ with an aggregate market value of $672,724.89. Total shares outstanding listed are 78,504,440. The 870 shares consist of 143 shares acquired on 06/26/2024 and 727 shares acquired on 08/13/2025, both from restricted stock vesting under a registered plan; payments are marked as Not Applicable. The filer states there have been no sales by the person in the past three months and includes the standard representation that no undisclosed material adverse information is known.
Axon Enterprise, Inc. (AXON) filed a Form 144 notifying a proposed sale of 100 shares of common stock through Morgan Stanley Smith Barney LLC, with an approximate aggregate market value of $75,254.34. The filing lists 78,504,440 shares outstanding for the issuer and an approximate sale date of 09/11/2025 on NASDAQ. The shares were acquired on 05/13/2024 as restricted stock vesting under a registered plan and payment was recorded on the same date. The filer reported no securities sold in the past three months and included the standard Rule 144 representation regarding absence of undisclosed material adverse information.
Axon CEO and director Patrick W. Smith reported sales of 10,000 shares of Axon Enterprise, Inc. (AXON) common stock executed on 09/08/2025 under a Rule 10b5-1 trading plan. The Form 4 lists 13 separate sell transactions that reduced his direct holdings to 3,043,982 shares following the sales. The filings state the trades were effected pursuant to a 10b5-1 plan adopted May 12, 2025, and executed in multiple trades with prices reported as weighted averages for each lot, with executed trade prices ranging from $734.22 to $749.00 per share. The Form 4 was signed on behalf of Mr. Smith by an attorney-in-fact.
Axon Enterprise, Inc. insider notice reports a proposed sale of 10,000 common shares through UBS Financial Services on Nasdaq with an aggregate market value of $7,436,415, dated for sale on 09/08/2025. The same block of 10,000 shares was acquired by option exercise on 11/15/2021 and paid in cash on that date. The filer also reported a prior sale of 10,000 common shares by Patrick W. Smith on 08/11/2025 for $8,312,887 in gross proceeds. The filing omits the issuer's address and the filing individual's CIK/CCC details.
Hadi Partovi, a director of Axon Enterprise, Inc. (AXON), reported a non-derivative transaction on 08/29/2025 reflecting a grant of 100 restricted stock units (RSUs) under the Axon Second Amended and Restated 2022 Stock Incentive Plan that vested in full on the grant date. The filing shows the RSUs were issued at a $0 price and that Mr. Partovi beneficially owned 238,038 shares following the transaction. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Partovi on 09/03/2025. The filing indicates the reporter is a director and the form was filed by one reporting person.
Brooks Cameron, Chief Revenue Officer of Axon Enterprise, reported a transaction on 09/02/2025 disposing of 749 shares of Axon common stock. The Form 4 states the shares were withheld to satisfy the reporting person’s tax liability from the vesting of restricted stock units, at a price of $747.29 per share. After the withholding, the reporting person beneficially owned 18,698 shares, held directly. The form was signed by an attorney-in-fact on 09/03/2025. No other transactions or derivative positions are reported.
Jeri Williams, a director of Axon Enterprise, Inc. (AXON), received 100 restricted shares on 08/29/2025 that vested in full on the grant date. The award was granted under the company’s Second Amended and Restated 2022 Stock Incentive Plan and carried a reported price of $0. After the transaction, Ms. Williams is reported to beneficially own 1,516 shares of Axon common stock on a direct basis. The Form 4 was signed on behalf of Ms. Williams by an attorney-in-fact on 09/03/2025.